Q5117 is a valid 2023 HCPCS Code that could be used to indicate Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg for reimbursement purposes.
Q5117 belongs to Medical Care Type of Service and has been in effect since Oct 01, 2019.
Inj., kanjinti, 10 mg
Q5117 code information
| HCPCS code: | Q5117 |
| Description: | INJECTION, TRASTUZUMAB-ANNS, BIOSIMILAR, (KANJINTI), 10 MG |
| Effective Date: | Oct 01, 2019 |
| Added Date: | Oct 01, 2019 |
| Termination Date: | HCPCS Q5117 was terminated on Nov 30, -0001 |
| Pricing indicator: | 51 - DRUGS |
| Multi Pricing indicator: | A - NOT APPLICABLE AS HCPCS PRICED UNDER ONE METHODOLOGY |
| Coverage code: | C - CARRIER JUDGMENT |
| BETOS code: | O1E - OTHER DRUGS |
| Action code: | N - NO MAINTENANCE FOR THIS CODE |
| Type of Service: |
1 - MEDICAL CARE
P - LUMP SUM PURCHASE OF DME, PROSTHETICS, ORTHOTICS
|
| Anesthesia BUQ: | 0 |
Below a selection of HCPCS codes related to Q5117